Rani's RT-114 Oral Capsule Shows Strong Bioavailability In Phase 1a Study; Phase 1b Underway
Rani Therapeutics (RANI) reported Phase 1a results for RT-114, an oral RaniPill capsule delivering PG-102, a GLP-1/GLP-2 dual agonist from ProGen. In 30 healthy volunteers, oral RT-114 produced >150% systemic exposure vs 12 mg subcutaneous, with similar half-life (5.6 vs 5.3 days) and no serious adverse events. Phase 1b is underway; data expected in 2027.
How this was made
The 30-second read
Why it matters
The new Phase 1a results show oral systemic exposure exceeding subcutaneous dosing with similar elimination half-life and no serious adverse events, strengthening the platform thesis and justifying continued clinical progression into repeat-dose Phase 1b.
Market read
Traders may reprice the probability of successful oral delivery based on the reported >150% exposure versus injection and the start of repeat-dose Phase 1b.
What to watch
The article provides PK exposure and mild GI side effects but no efficacy biomarkers, no food-effect details, and no capsule-specific safety signals beyond the short Phase 1a window.
Background
RT-114 (RaniPill capsule) is an orally administered delivery of PG-102, a GLP-1/GLP-2 dual agonist being developed by ProGen Co., Ltd.
Ticker impact
Rani Therapeutics reported Phase 1a data for RT-114, showing oral systemic exposure over 150% versus matched subcutaneous dosing.
Near-term upside bias versus prior expectations, but follow-through depends on Phase 1b repeat-dose PK and later patient efficacy.
The article discloses new Phase 1a oral vs injection exposure and safety, plus a defined Phase 1b design and timeline into 2027.
Market effects
Supports investor appetite for oral biologic delivery approaches in obesity/metabolic disease, but does not change the broader sector fundamentals.
Limited, microcap-specific sentiment impact likely confined to US small-cap biotech.
Low, as the program is early-stage and the article provides no cross-border regulatory or commercial milestones.
Counterpoint
Oral exposure outperformance in healthy volunteers may not translate into patient efficacy or tolerability, and the key readout is still Phase 1b and later obesity studies.
Key entities
- companyRani Therapeutics Holdings, Inc.
Subject of the announcement, reporting Phase 1a and initiating Phase 1b for RT-114 via the RaniPill platform.
- drug_programRT-114
Orally administered RaniPill capsule delivering PG-102; Phase 1a PK and tolerability data reported, Phase 1b underway.
- drug_programPG-102
GLP-1/GLP-2 dual agonist delivered subcutaneously as the comparator and via RaniPill in Phase 1b.
- companyProGen Co., Ltd.
Developer of PG-102, referenced as the source of the dual agonist being delivered by RT-114.
